Stocks attracting fund managers in November 2020
In November 2020, the healthcare sector gained over other sectors to be on the top of the fund managers’ buying list, followed by financials, automobile & ancillaries, and the technology sector.
|
Stock Name
|
Sector
|
Asset Class
|
Net Qty Bought
|
Approx. Buy Value (In Cr)
|
|
Gland Pharma Ltd
|
Healthcare
|
Large-Cap
|
1,63,47,108
|
3,454.14
|
|
Maruti Suzuki India Ltd
|
Automobile and Ancillaries
|
Large-Cap
|
10,16,385
|
711.47
|
|
HCL Technologies Ltd
|
Technology
|
Large-Cap
|
80,35,361
|
668.60
|
|
Crompton Greaves Consumer Electricals Ltd
|
Consumer Durables
|
Mid-Cap
|
2,11,57,571
|
639.59
|
|
Dr. Reddy’s Laboratories Ltd
|
Healthcare
|
Large-Cap
|
10,73,720
|
521.70
|
The above table shows that in the month of November 2020, the healthcare sector has come in the top five sectors’ preference of the fund managers. The total approximate buying done in the healthcare sector is Rs 4,338 crore. Gland Pharma Ltd and Dr Reddy’s Laboratories Ltd have made their way to the top five buying with a total approximate buying value of Rs 3,975.84 crore.
Further, under the total sector-wise buying done in the month of November 2020, the healthcare sector ranks on the top, followed by financials, automobile & ancillaries, technology and consumer durables sector with an approximate buying value of Rs 4,338.05 crore, Rs 2,412.44 crore, Rs 1,141.90 crore, Rs 1,113.09 crore, and Rs 680.73 crore, respectively.
If we look at the total buying done in the month of November 2020 market cap-wise, then large-cap would be seen at the top, followed by mid-cap and small-cap with an approximate buying value of Rs 7,176.23 crore, Rs 3,385.38 crore, and Rs 1,603.31 crore, respectively.
The intention of the above analysis is only for the purpose of understanding the activity of mutual funds and gauging the fund managers’ approach and it by no means, a recommendation to buy or sell. It is always advisable to have a financial plan in place, which must be followed with discipline and investments in mutual funds being made to be based on your individual risk assessment.